Compare · CMPS vs CMPX
CMPS vs CMPX
Side-by-side comparison of COMPASS Pathways Plc (CMPS) and Compass Therapeutics Inc. (CMPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CMPS focuses on Biotechnology: Pharmaceutical Preparations, while CMPX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CMPS is the larger of the two at $2.06B, about 4.5x CMPX ($455.6M).
- CMPS has been more active in the news (11 items in the past 4 weeks vs 4 for CMPX).
- CMPX has more recent analyst coverage (24 ratings vs 17 for CMPS).
- Company
- COMPASS Pathways Plc
- Compass Therapeutics Inc.
- Price
- -
- -
- Market cap
- $2.06B
- $455.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 4
- Recent ratings
- 17
- 24
COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest CMPS
- SEC Form 144 filed by COMPASS Pathways Plc
- SEC Form 144 filed by COMPASS Pathways Plc
- Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
- Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Executive Officer Nath Kabir covered exercise/tax liability with 5,962 units of Ordinary Shares, decreasing direct ownership by 2% to 361,028 units (SEC Form 4) to satisfy withholding obligation
- SEC Form S-3ASR filed by COMPASS Pathways Plc
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- COMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by COMPASS Pathways Plc
Latest CMPX
- SEC Form SCHEDULE 13G filed by Compass Therapeutics Inc.
- SEC Form 10-Q filed by Compass Therapeutics Inc.
- Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
- Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
- Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ladenburg Thalmann resumed coverage on Compass Therapeutics with a new price target
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
- Compass Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders